###begin article-title 0
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USP36</italic>
Differential display identifies overexpression of the USP36 gene, encoding a deubiquitinating enzyme, in ovarian cancer
###end article-title 0
###begin p 1
Conflict of Interests: The authors have declared that no conflict of interest exists.
###end p 1
###begin p 2
###xml 166 171 <span type="species:ncbi:9606">human</span>
Objectives. To find potential diagnostic markers or therapeutic targets, we used differential display technique to identify genes that are over or under expressed in human ovarian cancer.
###end p 2
###begin p 3
###xml 233 240 233 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 77 82 <span type="species:ncbi:9606">human</span>
Methods. Genes were initially identified by differential display between two human ovarian surface epithelium cultures and two ovarian cancer cell lines, A2780 and Caov-3. Genes were validated by relative quantitative RT-PCR and RNA in situ hybridization.
###end p 3
###begin p 4
###xml 339 346 339 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 610 618 <span type="species:ncbi:9606">patients</span>
###xml 658 663 <span type="species:ncbi:9606">women</span>
Results. Twenty-eight non-redundant sequences were expressed differentially in the normal ovarian epithelium and ovarian cancer cell lines. Seven of the 28 sequences showed differential expression between normal ovary and ovarian cancer tissue by RT-PCR. USP36 was over-expressed in ovarian cancer cell lines and tissues by RT-PCR and RNA in situ hybridization. Northern blot analysis and RT-PCR revealed two transcripts for USP36 in ovarian tissue. The major transcript was more specific for ovarian cancer and was detected by RT-PCR in 9/9 ovarian cancer tissues, 3/3 cancerous ascites, 5/14 (36%) sera from patients with ovarian cancer, and 0/7 sera from women without ovarian cancer.
###end p 4
###begin p 5
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USP36 </italic>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
Conclusion. USP36 is overexpressed in ovarian cancer compared to normal ovary and its transcripts were identified in ascites and serum of ovarian cancer patients.
###end p 5
###begin title 6
Introduction
###end title 6
###begin p 7
###xml 164 165 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 578 579 578 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 104 109 <span type="species:ncbi:9606">women</span>
###xml 169 174 <span type="species:ncbi:9606">woman</span>
###xml 645 653 <span type="species:ncbi:9606">patients</span>
Ovarian cancer, the most fatal gynecological cancer, is ranked fourth in overall cancer mortality among women in the United States, causing ~16,000 deaths per year 1. A woman's estimated risk of developing ovarian cancer in her lifetime is 1 in 70 or 1.4%. Unfortunately, no fully effective mass screening method for early ovarian cancer has yet been developed. The currently available methods, such as abdominal and transvaginal ultrasonography, color flow Doppler, and CA-125, are not specific enough for detecting early, treatable ovarian cancer through population screening 2. Therefore, the disease is detected at an advanced stage in most patients, being confined to the ovaries at diagnosis in fewer than 30% of cases.
###end p 7
###begin p 8
###xml 57 58 57 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 312 313 312 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 537 538 537 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 740 747 740 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 829 834 829 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USP36</italic>
###xml 910 915 910 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USP36</italic>
###xml 451 456 <span type="species:ncbi:9606">human</span>
###xml 644 649 <span type="species:ncbi:9606">human</span>
###xml 977 982 <span type="species:ncbi:9606">human</span>
###xml 1025 1030 <span type="species:ncbi:9606">women</span>
Epithelial ovarian cancer develops from a clone of cells 3, which suggests that early stages of the disease could be detected if specific tumor markers expressed at early stages could be identified. To find potential diagnostic markers for early ovarian cancer, we used differential display previously described 4 for identifying key genes that were uniquely overexpressed or silenced in ovarian cancer compared with normal cells. As more than 85% of human ovarian cancers are thought to be derived from ovarian surface epithelium (OSE) 5, we performed differential display to compare gene expression patterns in two cultured OSE cells and two human ovarian cancer cell lines, A2780 and Caov-3. We used relative quantitative RT-PCR and RNA in situ hybridization techniques to further evaluate the differentially expressed genes. USP36 was confirmed over-expressed in ovarian cancer cell lines and tissues. The USP36 predominant transcript was further characterized in multiple human tissues, cancerous ascites, and sera from women with and without ovarian cancer.
###end p 8
###begin p 9
###xml 587 588 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 674 675 674 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 677 678 677 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
In eukaryotic cells, ubiquitination and deubiquitination regulate a number of biological processes by balancing cellular protein degradation. This post-translational modification is a dynamic and reversible process controlled by the coordinate action of multiple ubiquitin-conjugating and deubiquitylating enzymes. USP36 is one of the deubiquitinating (DUB) enzymes and belongs to ubiquitin-specific processing proteases (USP). USP removes ubiquitin from specific protein substrates and allow protein salvage from proteasome degradation, regulation of protein localization or activation 6. Previous studies demonstrated that USP36 has DUB activity both in vivo and in vitro 7, 8.
###end p 9
###begin title 10
Materials and methods
###end title 10
###begin title 11
Cell cultures and tissue samples
###end title 11
###begin p 12
###xml 74 79 <span type="species:ncbi:9606">women</span>
###xml 122 127 <span type="species:ncbi:9606">human</span>
###xml 242 247 <span type="species:ncbi:9606">Human</span>
Tissue samples from normal ovaries and ovarian cancers were obtained from women undergoing oophorectomies. RNA from other human tissues was obtained from the Tissue Procurement Core at the Siteman Cancer Center. The study was approved by the Human Studies Committee of Washington University in St. Louis.
###end p 12
###begin p 13
###xml 79 80 79 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 341 342 341 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 369 371 369 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3 </sup>
###xml 557 558 548 549 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human OSE cells were collected according to the method described by Kruk et al 9 and cultures were maintained in a mixture of Medium 199 with Earle's balanced salt solution (Sigma, St. Louis, MO) and MCDB105 (Sigma, St. Louis, MO) (1:1, pH 7.3) supplemented with 15% FBS (medium 199/105/15% FBS) and 2 mM L-glutamine. The medium contained 103 IU/ml of penicillin and 103 mug/ml of streptomycin and fungizone (250 ng/ml) for the first week. Cells were plated onto a T25 polystyrene flask with 5 ml of medium and incubated undisturbed at 37masculineC in 5% CO2/air for 48 hours. The old medium, which contained blood and debris, was replaced with fresh prewarmed (37masculineC) medium. Subsequently, the culture medium was changed every 3-4 days as needed. When the culture was confluent, the cells were subcultured with trypsin/EDTA (Life Technologies, Gaithersburg, MD).
###end p 13
###begin p 14
To characterize the cultured cells, we added 3-4 drops (50-100 mul) of prewarmed medium into each well of a microscope slide well chamber (16 wells/slide). Two drops of trypsin/EDTA/cell mixture were seeded into each well. The medium was changed every 3-4 days until the cells were confluent. Then cells were fixed in methanol/acetone and stained for cytokeratin and vimentin using anti-cytokeratin AE1/AE3 (Boehringer Mannheim, Indianapolis, IN) and anti-vimentin (Boehringer Mannheim, Indianapolis, IN) following the manufacturer's instructions.
###end p 14
###begin p 15
To propagate the cells and extract their RNA, we placed the remaining trypsin/EDTA/cell mixture in a T75 polystyrene flask and added 10 ml of prewarmed (37masculineC) medium. The medium was changed on the next day to remove debris and then changed every 3-4 days. When the cells in the flask were confluent, they were trypsinized and RNA was extracted.
###end p 15
###begin p 16
###xml 197 198 197 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 225 226 225 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 288 289 287 288 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The A2780 cell line was cultured in RPMI 1640 medium. The Caov-3 cell line was cultured in Dulbecco's modified Eagle's medium (DMEM). Both media were supplemented with 10% FBS, 2 mM L-glutamine, 103 IU/ml of penicillin and 103 mug/ml of streptomycin. The cell lines were cultured in 5% CO2 at 37masculineC.
###end p 16
###begin title 17
Differential display
###end title 17
###begin p 18
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 148 150 148 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 265 266 265 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 390 392 390 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
Total cellular RNA was isolated from the cell lines by the guanidinium isothiocyanate method 10. Contaminating DNA was removed with the MessageCleanTM Kit (GenHunter Co., Nashville, TN). Differential display technique was first described by Liang and Pardee in 19924. Since then the technique has been applied in numerous studies. We performanced the differential display using the RNAimageTM kit (GenHunter Co. Nashville, TN), following the manufacturer's instructions.
###end p 18
###begin p 19
###xml 236 238 236 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
Total RNA was reverse transcribed using the primer H-T11A (5'-AAGCTTTTTTTTTTTA-3'), H-T11G (5'-AAGCTTTTTTTTTTTG-3'), or H-T11C (5'-AAGCTTTTTTTTTTTC-3'). The product was amplified by PCR using one of the primer pairs labeled with alpha-[35S]-dATP. Overall, 24 primer pairs were used for PCR, including combinations of each of the above three primers with H-AP49 (5'-AAGCTTTAGTCCA-3'), H-AP50 (5'-AAGCTTTGAGACT-3'), H-AP51 (5'-AAGCTTCGAAATG-3'), H-AP52 (5'-AAGCTTGACCTTT-3'), H-AP53 (5'-AAGCTTCCTCTAT-3'), H-AP54 (5'-AAGCTTTTGAGGT-3'), H-AP55 (5'-AAGCTTACGTTAG-3'), or H-AP56 (5'-AAGCTTATGAAGG-3'). All PCR products were electrophoresed in parallel on extended-format denaturing 6% polyacrylamide gel and displayed by autoradiography.
###end p 19
###begin title 20
cDNA cloning and sequencing
###end title 20
###begin p 21
###xml 340 342 340 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 538 540 538 540 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 547 549 547 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
PCR products of the RNAs that were found to be differentially expressed between OSE cell lines and ovarian cancer cell lines were cut out from a polyacrylamide gel, re-amplified with the same primer pair, purified on agarose gels using the QIAquick Gel Extraction Kit (QIAGEN, Valencia, CA), and then cloned into the pCR-TRAP Cloning SystemTM (GenHunter Co., Nashville, TN). The inserts of clones were sequenced using either the Lgh and or Rgh primer flanking the cloning site. All sequencing reactions were performed ustilizing ABI PRISMTM BigDyeTM Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer, Foster City, CA).
###end p 21
###begin title 22
RT-PCR
###end title 22
###begin p 23
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 181 184 179 182 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">260</sub>
###xml 368 370 363 365 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">15</sub>
###xml 454 455 449 450 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Relative quantitative RT-PCR was performed according to the method of Nicoletti and Sassy-Prigent 11, with some modification. RNA samples were diluted to 1 mug/4 mul (assessed by OD260). One mug of each mixed RNA (normal and cancer) sample was used for reverse transcription in a reaction mixture whose final volume was 20 mul. The mixture contained 1 mug of oligo(dT)15, 200 U of MMLV reverse transcriptase, 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM dithiothreitol (DTT), 20 U RNase inhibitor (Promega, Madison, WI), and 0.5 mM each of dNTP and 0.1% DEPC (Sigma, St. Louis, MO). It was incubated at 37masculineC for 60 min.
###end p 23
###begin p 24
###xml 219 220 216 217 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 319 359 316 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">glyceraldehyde-3-phosphate dehydrogenase</italic>
###xml 594 596 559 561 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">20</sub>
The primers were designed using the Primer 3 program (). Multiplex PCR was performed in a total volume of 20 mul that contained 0.5 muM of each primer, 500 muM each of dNTP, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 6 mM MgCl2 and 2.5 U of AmpliTaq DNA Polymerase (Perkin-Elmer, Norwalk, CT). An endogenous housekeeper gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal standard to correct for tube-to-tube variations in amplification efficiency. The PCR thermocycles were: 4 min at 94masculineC, (1.5 min at 94masculineC, 2 min at 55masculineC, and 3 min at 72masculineC)20, and 10 min at 72masculineC. A minus RT-PCR reaction was included for every RNA sample to confirm the absence of contaminating DNA.
###end p 24
###begin p 25
Quantitative data on the PCR products were acquired by digitizing photographs of ethidium bromide-stained agarose gel into gray-scale images using the public NIH Image 1.71 program and by the Wave DNA Fragment Analysis System (Transgenomic, Omaha, NE).
###end p 25
###begin title 26
RNA in situ hybridization
###end title 26
###begin p 27
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 1743 1748 <span type="species:ncbi:9940">sheep</span>
RNA in situ hybridization was performed using a digoxigenin (DIG) labeled riboprobe. Sense and antisense riboprobes were synthesized separately and labeled in total volume of 20 microl. The reaction mixture contained 1 x transcription buffer, 1 x DIG RNA labeling mixture from the DIG Genius 4 RNA Labeling Kit (Boehringer Mannheim, Indianapolis, IN), 5 mM DTT, 20 U of RNase inhibitor (Promega, Madison, WI), 40 U of T7 or SP6 RNA polymerase (Promega, Madison, WI), and 60 ng of linearized DNA templates. The templates were generated from the PCR products amplified using T7 and SP6 primer (GenHunter Co., Nashville, TN) from IMAGE clone 2400019. The generated antisense probe for USP36 is 267bp (5'- ggatccatttaggtgacactatagaagtacctgaaaggaagcttttttttttcgaggatttcctgtatttattaagttacaagttggcaggcacagcttgagcaacatagaaaagtaatcttcttgagttatacaatcatttaaattccaaagcactcacaaaattgagcaaacaaagccactatttgcatatttgggaaaggaaacatattgctaacgtaagcttcctgaatccttcatggcctatagtgagtcgtattagaattc-3'). The synthesized riboprobe was precipitated by ethanol and verified by RNA electrophoresis. Formalin-fixed paraffin-embedded tissue slides were deparaffinized in Hemo-De (Fisher Scientific, Pittsburgh, PA), rehydrated in serially diluted ethanol (100%, 95%, 70%, 50%, and 30%), digested in 2 microg/ml proteinase K at 37masculineC for 30 min, and then rinsed 3 times in PBT (PBS containing 0.1% Tween 20 and 0.1% DEPC). The pretreated slides were hybridized at 55masculineC overnight in a buffer containing 50% formamide, 5 x SSC, 100 microg/ml Salmon Sperm DNA, 100 microg/ml heparin, 0.1% Tween 20, 1 x Denhardt's medium, 0.1% CHAPS, 5 mM EDTA, and ~16 microg/ml DIG-labeled riboprobe. After the slides were rinsed with 0.1 x SSC and blocked with blocking buffer (5% sheep serum, 2 mg/ml BSA, and 1% DMSO in PBT), DIG-labeled riboprobe was detected with anti-digoxigenin-AP, Fab fragments (Boehringer Mannheim, Indianapolis, IN), according to manufacture's instructions.
###end p 27
###begin title 28
Northern blot
###end title 28
###begin p 29
###xml 248 250 248 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 340 342 340 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 456 458 456 458 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 927 928 927 928 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 954 955 954 955 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 973 975 973 975 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
mRNA was extracted by the Messenger RNA standard isolation kit (Sigma, St. Louis, MO), and total RNA was extracted by the ToTALLY RNA kit (Ambion, Austin, TX). The products were electrophoresed on 1.5% formaldehyde/1% agarose gel with RNA MilenniumTM Size Marker (Ambion, Austin, TX). The RNA was transferred from the gel to BrightStar-PlusTM Membranes (Ambion, Austin, TX) and cross-linked onto the membrane with UV. Single-strand DNA probes labeled with 32P dCTP were made by asymmetric PCR, using antisense primer and same template as in RNA in situ hybridization. The synthesized probe was purified on a centrifuge column, and its specific activity was measured by liquid scintillation analysis. The probe for USP36 is 130bp (5'- ttacaagttggcaggcacagcttgagcaacatagaaaagtaatcttcttgagttatacaatcatttaaattccaaagcactcacaaaattgagcaaacaaagccactatttgcatatttgggaaaggaaa-3'). The membrane was hybridized in buffer containing 1.6 x 107 cpm/ml probe and 6.0 x 104 cpm RNA MilenniumTM Size Marker (Ambion, Austin TX) at 50masculineC for 16 h. The membrane was rinsed with low stringency solution 2 x SSC and 0.1% SDS at 50masculineC for 15 min and then autoradiographed at -70masculineC with intensifier screen.
###end p 29
###begin title 30
Isolation of RNA from ascites and serum
###end title 30
###begin p 31
###xml 362 364 336 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 493 494 467 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 570 572 544 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 937 939 909 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
Serum was isolated and stored at -70masculineC until processed. Ascites was collected at surgery and centrifuged at 4masculineC for 5 minutes at 150g. The supernatant was removed and stored at -70masculineC until processed. Isolation of RNA was preformed using TRIzol(R) LS Reagent (Invitrogen Corporation, Carlsbad, CA) or magnetic bead method - Ambion's MagMaxTM technology (Ambion, Inc., Austin, TX) following manufactures' protocol. DNA and RNA input levels ranging from 20 copies to 25x106 copies can be quantitatively recovered from plasma, serum, and milk (MagMaxTM manual). The concentration and purity of RNA were determined by using the Nanodrop(R) ND-1000A UV-Vis Spectrophotometer (NanoDrop Technologies, Wilmington, DE) and Agilent 2100 Bioanalyzer (Agilent Technologies, Inc. Santa Clara, CA). The concentration of RNA extracted from the sera range from 0.2 ~ 26ng/ul, which is similar with the results from a recent study 12. RNA was processed for cDNA using Ambion RETROscript(R) Kit (Ambion, Inc.Austin,TX). An internal standard, RPS14, was used to confirm the RNA quality suitable for RT-PCR.
###end p 31
###begin title 32
Results
###end title 32
###begin title 33
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human OSE cell lines
###end title 33
###begin p 34
###xml 196 201 <span type="species:ncbi:9606">human</span>
###xml 626 631 <span type="species:ncbi:9606">human</span>
Cultures of OSE cells were characterized by immunostaining with monoclonal antibodies, anti-keratin AE1/AE3 and anti-vimentin. The anti-keratin AE1/AE3 monoclonal antibody specifically recognizes human epithelial cytokeratin, an intermediate filament in epithelial cells that is absent from mesenchymal cells such as fibroblasts and smooth muscle cells. The anti-vimentin monoclonal antibody was used to stain cells of mesenchymal origin, including endothelial cells, vascular smooth muscle cells, connective tissue cells, and all types of blood cells. Immunostaining with both antibodies confirmed the epithelial origin of 6 human OSE cell cultures and 2 cell lines (N 1/4 and N 1/29) were used for the differential display.
###end p 34
###begin title 35
###xml 39 44 <span type="species:ncbi:9606">human</span>
Genes expressed differentially between human OSE cells and ovarian cancer cell lines
###end title 35
###begin p 36
###xml 387 388 387 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 61 66 <span type="species:ncbi:9606">human</span>
Thirty-one bands were differentially expressed between the 2 human OSE cell lines and 2 ovarian cancer cell lines (A2780 and Caov-3). Among those 31 bands, 15 were significantly overexpressed in the two ovarian cancer cell lines compared with the two normal OSE cell lines and 16 were expressed at lower levels in the two ovarian cancer cell lines than in the two OSE cell lines. Figure 1 provides an example of differential expression.
###end p 36
###begin p 37
We cloned all 31 differentially expressed bands into pCR-TRAP vectors. The clones were screened according to the size of the inserts, using PCR and the primer pair that flanked the cloning site of the pCR-TRAP vector and then sequenced. For two bands, two different sequences with similar sizes were identified. Therefore, a total of 33 different cloned sequences were obtained.
###end p 37
###begin p 38
###xml 497 498 497 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
To identify these sequences, we used the blastn algorithm to query three nucleotide sequence databases on the NCBI website (): nr (non-redundant), dbEST, and dbSTS. The 33 clones represented 28 nonredundant sequences. Fourteen were underexpressed in both cancer cells lines and 14 were overexpressed in both cancer cell lines. Among the 28 nonredundant sequences, 22 matched known genes or EST, rest of them either matched to genomic DNA that contained no known EST or intron of known gene (Table 1).
###end p 38
###begin title 39
###xml 41 46 <span type="species:ncbi:9606">human</span>
Validation of differential expression in human ovarian tissues
###end title 39
###begin p 40
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1123 1128 1123 1128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 1473 1474 1473 1474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 1479 1480 1479 1480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 91 96 <span type="species:ncbi:9606">human</span>
###xml 192 197 <span type="species:ncbi:9606">human</span>
###xml 253 258 <span type="species:ncbi:9606">human</span>
To confirm that the 28 non-redundant sequences were expressed differentially in the normal human ovary and ovarian cancer tissues, we performed relative quantitative RT-PCR, using four normal human ovary tissue samples (NO1, NO2, NO3, and NO4) and four human ovarian cancer tissue samples (OC1, OC2, OC3 and OC4). To obtain a relative quantitative measurement of the gene expression, an alternative quantitative PCR method was used 11. First, a series of 5 progressive dilutions achieved by mixing RNAs of tumor (T) and matched normal (N) samples (T4/N0, T3/N1, T2/N2, T1/N3 and T0/N4) were assembly. Then an aliquot of each dilution mix was submitted to a standard RT-PCR. After PCR, the photographs of ethidium of bromide-stained gels were digitized into gray-scale images. The amount of nucleic acids was determined by densitometry. The amount of nucleic acid was proportional to the log of the optic density. The sum of the logarithms of the pixel values was used to estimate the amount of nucleic acid in a band. The fold increase was compared based on the expression of normal sample (T0/N4). The internal control of GAPDH was used to correct for tube-to-tube variations in initial sample inputting. In addition, we did the semi-quantitative RT-PCR using minimal cycling to avoid the artificial effect of saturation of PCR products. Seven of the 28 sequences showed differential expression between the normal and cancer tissues by relative quantitative RT-PCR (Table 2 and 3).
###end p 40
###begin p 41
###xml 623 624 623 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 755 756 755 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 484 492 <span type="species:ncbi:9606">patients</span>
The three over-expressed sequences in ovarian cancer tissue confirmed by RT-PCR were USP36, RMND5A, and POLR3E. We further evaluated the expression of these 3 genes by RNA in situ hybridization, using nine ovarian cancer tissues (including endometroid adenocarcinoma, serous adenocarcinoma, borderline serous tumor, papillary serous adenocarcinoma, clear cell adenocarcinoma, and mixed epithelial type adenocarcinoma) and eight matched normal ovaries or fallopian tubes from the same patients. A sense probe was used as the negative control. For USP36, all nine ovarian cancer tissues gave a strong positive signal (Figure 2, panels A-D) and eight normal tissues gave very weak or negative results in the surface epithelium, stroma, and follicles (Figure 2, panels E and F). For RMND5A, six of the nine ovarian cancer tissues were positive and all the normal tissues were weak or negative. For POLR3E, four of the nine ovarian cancer tissues gave positive results and all the normal tissues showed weak or negative staining.
###end p 41
###begin title 42
The predominant transcripts of USP36 and RMND5A in ovarian cancer cell lines
###end title 42
###begin p 43
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USP36</italic>
###xml 125 126 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3</xref>
###xml 129 134 129 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USP36</italic>
###xml 503 508 503 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USP36</italic>
###xml 522 523 522 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4</xref>
###xml 683 684 683 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3</xref>
###xml 744 745 744 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 750 751 750 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 899 900 899 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4</xref>
###xml 252 257 <span type="species:ncbi:9606">human</span>
Northern blot analysis revealed two transcripts for USP36, ~6.0 kb (major transcript) and ~4.7 kb (minor transcript) (Figure 3). USP36 locates on chromosome 17q25.3 and covers 44571 bp genomic sequences. Seventeen mRNAs and 482 EST sequences represent human USP36 in NCBI UniGene database (). The ESTs come from almost every tissue, including ovary and cervix. The sequence alignment between representative mRNA and the genomic sequence indicates that these mRNAs are spliced transcript variants of the USP36 gene (Figure 4). Among these mRNAs, AB040886 (NM_025090, 5879 bp) and AK022840 (4650 bp) most closely match the major and minor transcripts seen in the Northern blot (Figure 3). The sequence from the differential display band F (Table 2 and 3) perfectly matches both mRNAs, but only the AK022840 transcript contained the homologous 3' end identified by initial differential display (Figure 4).
###end p 43
###begin p 44
###xml 125 126 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">4</xref>
###xml 135 136 135 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4</xref>
###xml 386 387 386 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5</xref>
To confirm which transcripts are expressed in ovarian cancer, we designed 6 RT-PCR primers that detect specific mRNAs (Table 4, Figure 4). All primer pairs except USP36-2 were designed to cross an intron to eliminate interference by any contaminating genomic DNA. RT-PCR results demonstrated the expression of AB040886 (~ 6 kb) and AK022840 (~4 kb) in ovarian cancer cell lines (Figure 5) and were consistent with the Northern blot results. AB040886 has 21 exons, encodes a protein with 1121 amino acid (aa) and contains one ubiquitin carboxyl-terminal hydrolase (UCH) family 2 motif. AK022840 has 16 exons and encodes a protein with 726 aa and contains part of the ubiquitin carboxyl-terminal hydrolase (UCH) domain.
###end p 44
###begin p 45
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RMND5A</italic>
###xml 139 140 139 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3</xref>
###xml 156 162 156 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RMND5A</italic>
###xml 579 581 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
Northern blot analysis revealed two transcripts for RMND5A (~6.0 kb and ~2.5 kb) by using mRNA from ovarian cancer cell line A2780 (Figure 3). The sequence RMND5A resides on chromosome 2p11.2 and covers 57756 bp genomic sequences. Several mRNAs corresponding to this gene are documented on the NCBI website. Recent study showed that RMND5A (p44CTLH) was associated with several proteins and composed a large protein complexes. It contains LisH/CTLH motifs, which are present in proteins involved in microtubule dynamics, cell migration, nucleokinesis, and chromosome segregation 13.
###end p 45
###begin title 46
###xml 57 62 <span type="species:ncbi:9606">human</span>
Expression pattern of USP36 mRNA transcripts in multiple human tissues
###end title 46
###begin p 47
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USP36</italic>
###xml 237 238 237 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">4</xref>
###xml 113 118 <span type="species:ncbi:9606">human</span>
###xml 403 408 <span type="species:ncbi:9606">human</span>
###xml 475 483 <span type="species:ncbi:9606">patients</span>
###xml 525 533 <span type="species:ncbi:9606">patients</span>
###xml 627 632 <span type="species:ncbi:9606">women</span>
We further evaluated the expression of USP36 major transcript AB040886 and minor transcript AK022840 in multiple human tissues by RT-PCR. USP36-3A was developed to identify AB040886 with a smaller PCR product in serum and ascites (Table 4). The results showed that the major transcript AB040886 is more specific for ovarian cancer tissue than the minor transcript AK022840. AB040886 was detected in 9/9 human ovarian cancer tissues, 3/3 ascites specimens from ovarian cancer patients, and 5/14 (36%) sera from ovarian cancer patients. Sequencing two of five PCR products from sera confirmed the result. None of seven sera from women without ovarian cancer detected AB040886.
###end p 47
###begin p 48
As comparison to ovarian cancer, 4 normal ovaries tissues showed absent expression except one hemorrhagic torsed benign ovary had expression similar to ovarian cancer. In addition, AB040886 showed absent expression in normal tissues from pancreas, kidney, cervix, spleen, testis, endometrium, breast, colon, myometrium, and liver by RT-PCR. There was minimal to absent staining in cancers from prostate, cervix, colon, lung and breast. AK022840 was ubiquitously expressed in all tested tissues.
###end p 48
###begin title 49
Discussion
###end title 49
###begin p 50
###xml 244 251 244 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 391 396 391 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USP36</italic>
###xml 474 481 474 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 503 508 503 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USP36</italic>
###xml 103 108 <span type="species:ncbi:9606">human</span>
###xml 140 145 <span type="species:ncbi:9606">human</span>
###xml 328 333 <span type="species:ncbi:9606">human</span>
To identify overexpressed or silenced genes in ovarian cancer, we used differential display to compare human ovarian cancer cell lines with human normal OSE cell lines. We detected 28 differentially expressed genes. When we used RT-PCR and RNA in situ hybridization to validate the differential expression of these sequences in human normal ovarian tissue and ovarian cancers and found that USP36 was consistently overexpressed in the ovarian cancers tissues evaluated. RNA in situ hybridization showed USP36 expression in various histologic types of epithelial ovarian cancer. Northern blot and RT-PCR identified two transcripts. The major transcript AB040886 appears more specific for ovarian cancer tissue than the minor transcript AK022840.
###end p 50
###begin p 51
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USP36</italic>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 879 881 879 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 883 885 883 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
USP36 is a deubiquitinating enzyme, also known as ubiquitin specific protease (USP). The deubiquitinating enzymes are a component of the ubiquitin system, which is important for regulating numerous basic biological processes, including cell-cycle progression, apoptosis, signal transduction, transcriptional regulation, receptor downregulation, and endocytosis 14. Like protein phosphorylation and dephosphorylation, protein ubiquitination is a dynamic process. It is controlled by the coordinated actions of ubiquitin conjugating enzymes and deubiquitinating enzymes that respectively add or remove the ubiquitin moiety from a target protein. The deubiquitinating enzymes are also involved in processing of poly-ubiquitin precursors into ubiquitin monomers, targeting or salvage of proteasomal substrates and regulating nonproteolytic functions of mono- and poly-ubiquitination 15, 16.
###end p 51
###begin p 52
###xml 179 181 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 428 430 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 432 434 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 557 561 554 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kip1</sup>
###xml 561 563 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 681 683 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 436 441 <span type="species:ncbi:4932">Yeast</span>
###xml 646 650 <span type="species:ncbi:10090">mice</span>
Ubiquitin-mediated proteolysis has been implicated in the degradation of several important oncogene products, such as N-myc, c-myc, c-fos, c-jun, beta-catenin, and adenovirus E1A 14. Aberrations in their removal may derail the cell cycle and result in malignant transformation. UCH-L1, a deubiquitinating enzyme, is highly expressed in primary lung cancers and lung cancer cell lines and strongly correlates with advanced stage 17, 18. Yeast two-hybrid analysis showed UCH-L1 interacts with JAB1, a Jun activation domain binding protein that can bind to p27Kip119. Another deubiquitinating enzyme, Unp (USP4) is tumorigenic when overexpressed in mice, acting like a proto-oncogene 20.
###end p 52
###begin p 53
###xml 62 67 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 326 327 326 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 633 639 633 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 670 675 670 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DUB-1</italic>
###xml 754 755 754 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 757 759 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 872 874 872 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 922 928 922 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DUB-1 </italic>
###xml 1222 1223 1222 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5</xref>
###xml 95 100 <span type="species:ncbi:9606">human</span>
###xml 1182 1187 <span type="species:ncbi:9606">human</span>
USP36 cloning and enzymatic analysis was published by Quesada et al. along with 21 other novel human ubiquitin-specific proteases. Northern blot analysis showed USP36 to be present in leukocytes, ovary, testis, and prostate at about ~ 7.5 kb (probe information not provided, there is no size marker to indicate the band size) 8. According to the provided protein IDs in the paper, NP_079366 matches USP36. The protein is 1123aa and the encoding mRNA is NM_025090 (5234bp) (). It is exactly the same protein we described in this study (AB040886, encoding USP36, 1123aa). Enzymatic assays demonstrated that USP36 had USP activity. Kim et al. identified USP36, called HeLa DUB-1, in extracts from HeLa by RT-PCR with a pair of primers designed for AK022913 7, 21. Although these publications stated USP36 was isolated from ovarian cancer, HeLa is a cervical cancer cell line 22. According to the published sequence, the HeLa DUB-1 cDNA is a different transcript from the major transcript (AB040886) of ovarian cancer cell lines described in this paper and corresponds to AK022913 (but with different 3' and 5' terminals). Our RT-PCR results indicated that AK022913 is not expressed in human ovarian cancer cell lines (Figure 5, lane 5). In Kim's paper, they mentioned that USP36 contains 18 exons. According to the same website  (version March 2006), USP36 contain 21 exons, in which 18 of them are coding exons.
###end p 53
###begin p 54
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 579 581 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 730 732 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 759 764 759 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USP36</italic>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
###xml 359 367 <span type="species:ncbi:9606">patients</span>
###xml 501 509 <span type="species:ncbi:9606">patients</span>
###xml 640 648 <span type="species:ncbi:9606">patients</span>
###xml 837 845 <span type="species:ncbi:9606">patients</span>
Circulating nucleic acids (CNA) was first reported in 1940s. In 1977, Leon et al. first reported high levels of CNA in patients with pancreatic cancer. In 2007 the use of CNA was proposed as a non-invasive tool for the early detection of cancer 23. Recent studies have shown circulating RNA may be used as a valuable diagnostic tool for discriminating cancer patients from non-cancer individuals. Li et al. demonstrated that the mRNA profile was more complex in sera from oral squamous cell carcinoma patients than that in healthy controls using microarray and RT-PCR techniques 24. Feng et al. found that the mean level of RNA in serum of patients with renal cell cancer was significantly higher than that in healthy individuals.12 Here we demonstrated that USP36 mRNA could be detected in 5/14 (36%) sera by RT-PCR from ovarian cancer patients. Additional studies are needed to validate these findings.
###end p 54
###begin p 55
###xml 56 63 56 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 113 118 113 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USP36</italic>
###xml 171 176 171 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USP36</italic>
###xml 347 352 347 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USP36</italic>
###xml 122 127 <span type="species:ncbi:9606">human</span>
###xml 276 284 <span type="species:ncbi:9606">patients</span>
In summary, using differential display, RT-PCR, and RNA in situ hybridization we confirmed the overexpression of USP36 in human ovarian cancer compared to normal ovaries. USP36 was detectable by RT-PCR in ovarian cancer tissue, ascites and serum specimens from ovarian cancer patients. Further work is necessary to identify the specific target of USP36 and to determine the role of this deubiquitinating enzyme in ovarian carcinogenesis or its prospect as a cancer biomarker.
###end p 55
###begin title 56
Abbreviations
###end title 56
###begin p 57
the ovarian surface epithelium
###end p 57
###begin p 58
glyceraldehyde-3-phosphate dehydrogenase.
###end p 58
###begin p 59
The work was supported by grants from the Siteman Cancer Center (supported in part by P30 CA91842), Barnes-Jewish Hospital Foundation and NIH grants CA094141 and CA95713. We would like to thank John Donaldson for his assistance in cell culture and Dr. Mark Watson for critical review of this manuscript.
###end p 59
###begin article-title 60
Cancer statistics, 2006
###end article-title 60
###begin article-title 61
Recent developments in ovarian cancer screening
###end article-title 61
###begin article-title 62
###xml 52 57 <span type="species:ncbi:9606">human</span>
Molecular genetic evidence of a unifocal origin for human serous ovarian carcinomas
###end article-title 62
###begin article-title 63
Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction
###end article-title 63
###begin article-title 64
Ovarian tumors. A review
###end article-title 64
###begin article-title 65
Targeting ubiquitin specific proteases for drug discovery
###end article-title 65
###begin article-title 66
Deubiquitinating enzyme USP36 contains the PEST motif and is polyubiquitinated
###end article-title 66
###begin article-title 67
###xml 43 48 <span type="species:ncbi:9606">human</span>
Cloning and enzymatic analysis of 22 novel human ubiquitin-specific proteases
###end article-title 67
###begin article-title 68
###xml 31 36 <span type="species:ncbi:9606">human</span>
A simplified method to culture human ovarian surface epithelium
###end article-title 68
###begin article-title 69
Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease
###end article-title 69
###begin article-title 70
An alternative quantitative polymerase chain reaction method
###end article-title 70
###begin article-title 71
###xml 34 42 <span type="species:ncbi:9606">patients</span>
Elevated serum-circulating RNA in patients with conventional renal cell cancer
###end article-title 71
###begin article-title 72
RanBPM, Muskelin, p48EMLP, p44CTLH, and the armadillo-repeat proteins ARMC8alpha and ARMC8beta are components of the CTLH complex
###end article-title 72
###begin article-title 73
###xml 53 58 <span type="species:ncbi:9606">human</span>
The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanism-based drug targeting
###end article-title 73
###begin article-title 74
Deubiquitinating enzymes--the importance of driving in reverse along the ubiquitin-proteasome pathway
###end article-title 74
###begin article-title 75
###xml 91 96 <span type="species:ncbi:9606">human</span>
Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells
###end article-title 75
###begin article-title 76
Serial analysis of gene expression in non-small cell lung cancer
###end article-title 76
###begin article-title 77
PGP9.5 as a candidate tumor marker for non-small-cell lung cancer
###end article-title 77
###begin article-title 78
Interaction and colocalization of PGP9.5 with JAB1 and p27(Kip1)
###end article-title 78
###begin article-title 79
###xml 68 73 <span type="species:ncbi:10090">mouse</span>
###xml 74 79 <span type="species:ncbi:9606">human</span>
Characterization of the ubiquitin-specific protease activity of the mouse/human Unp/Unph oncoprotein
###end article-title 79
###begin article-title 80
###xml 79 84 <span type="species:ncbi:9606">human</span>
A novel cysteine protease HeLa DUB-1 responsible for cleaving the ubiquitin in human ovarian cancer cells
###end article-title 80
###begin article-title 81
HeLa cells 50 years on: the good, the bad and the ugly
###end article-title 81
###begin article-title 82
###xml 101 106 <span type="species:ncbi:9606">human</span>
Circulating (cell-free) nucleic acids--a promising, non-invasive tool for early detection of several human diseases
###end article-title 82
###begin article-title 83
###xml 18 23 <span type="species:ncbi:9606">human</span>
Serum circulating human mRNA profiling and its utility for oral cancer detection
###end article-title 83
###begin p 84
###xml 24 29 <span type="species:ncbi:9606">human</span>
###xml 304 309 <span type="species:ncbi:9606">human</span>
###xml 456 461 <span type="species:ncbi:9606">human</span>
Differential display of human OSE cells and ovarian cancer cell lines. Each vertical panel represents one primer pair, and every primer pair includes 4 different cell lines: N1 (N1/4), N2 (N1/29), C1 (A2780), and C2 (Coav-3). The left panel shows bands that are expressed at a higher level in the normal human OSE cell lines N1/4 and N1/29 (bands A, B, C, and D) than in the cancer cell lines. The right panel shows the bands that are overexpressed in the human ovarian cancer cell lines A2780 and Coav-3 (bands E, F, and G). G1 and G2 are different bands with identical sequences.
###end p 84
###begin p 85
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> USP36</italic>
RNA in situ hybridization of USP36. A and B show a well-differentiated endometrioid adenocarcinoma hybridized with antisense (A) and sense (B) riboprobe. C and D show a poorly differentiated carcinoma of mixed epithelial origin, endometrioid, and papillary serous hybridized with antisense (C) and sense (D) riboprobe. E and F are from normal ovary hybridized with antisense (E) and sense (F) riboprobe.
###end p 85
###begin p 86
###xml 184 190 180 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RMND5A</italic>
Northern blot. Lanes A and C are RNA Size Marker; lanes B and D are mRNAs (10 microg polyA RNA in each lane) from the A2780 cell line. The first panel is USP36 and the second panel is RMND5A.
###end p 86
###begin p 87
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USP36</italic>
Transcripts for USP36 and primer location. A. Schematic representation of five USP36 transcripts from cDNA clones. Tel: telomere end; Cen: centromere end. B. The positions of five primers and band F are indicated schematically. Each RT-PCR primer is designed to cross introns (except primer USP36-2) and to detect a specific mRNA transcript.
###end p 87
###begin p 88
###xml 446 447 446 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4</xref>
Determination of USP36 transcripts by RT-PCR. Column 1-5 represent primers USP36-1 to USP36-5, and column M represents a 100 bp DNA ladder. Primers USP36-1 (AK022840) and USP36-3 (AB040886, NM_025090) were positive. Primer pairs USP36-4 (AI963973) and USP36-2 (AK023077) represent genomic DNA. Primer USP36-5 (AK022913) detected a 389 bp band which matches AB040886 and AK022840 but was negative for the 247 bp band specific for AK022913 (Figure 4).
###end p 88
###begin p 89
Genes (EST) identified in this study.
###end p 89
###begin p 90
###xml 72 73 72 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 83 84 83 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
*Band: differentially expressed genes, which validated by RT-PCR (Table 2 and Table3), in normal or tumor ovary cell lines.
###end p 90
###begin p 91
**N/A: not available
###end p 91
###begin p 92
Genes identified by differential display (increased in normal ovary or ovarian cancer) and validated by RT-PCR.
###end p 92
###begin p 93
###xml 61 66 <span type="species:ncbi:9606">human</span>
###xml 90 95 <span type="species:ncbi:9606">human</span>
Relative expression levels of the seven genes in four normal human ovary tissues and four human ovarian cancer tissues.
###end p 93
###begin p 94
ND: No data;
###end p 94
###begin p 95
-: no increase or increase < 2 times;
###end p 95
###begin p 96
+: Increased 2~10 times; ++: Increased 10~100 times; +++: Increased 100~1000 times; ++++: Increased more than 1000 times;
###end p 96
###begin p 97
NO = normal ovary, OC = ovarian cancer
###end p 97
###begin p 98
RT-PCR primer set and target mRNA.
###end p 98
###begin p 99
* USP36-5 primer set also detects AK022840 and AB040886 as a 389 bp PCR product.
###end p 99

